Skye Bioscience, Debt To Equity vs. Cash Per Share
| SKYE Stock | USD 2.46 0.20 7.52% |
Debt To Equity | First Reported 2010-12-31 | Previous Quarter (2.05) | Current Value (1.95) | Quarterly Volatility 1.20330221 |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.7 | 0.71 |
|
|
For Skye Bioscience, profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Skye Bioscience, to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Skye Bioscience, Common utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Skye Bioscience,'s most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Skye Bioscience, Common over time as well as its relative position and ranking within its peers.
Skye |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.60) | Return On Assets (0.30) | Return On Equity (0.55) |
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Skye Bioscience, Common Cash Per Share vs. Debt To Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Skye Bioscience,'s current stock value. Our valuation model uses many indicators to compare Skye Bioscience, value to that of its competitors to determine the firm's financial worth. Skye Bioscience, Common is rated second in debt to equity category among its peers. It is rated below average in cash per share category among its peers fabricating about 0.01 of Cash Per Share per Debt To Equity. The ratio of Debt To Equity to Cash Per Share for Skye Bioscience, Common is roughly 83.60 . At present, Skye Bioscience,'s Debt To Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Skye Bioscience, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Skye Cash Per Share vs. Debt To Equity
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Skye Bioscience, |
| = | 0.84 % |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Skye Bioscience, |
| = | 0.01 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Skye Cash Per Share Comparison
Skye Bioscience, is currently under evaluation in cash per share category among its peers.
Skye Bioscience, Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Skye Bioscience,, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Skye Bioscience, will eventually generate negative long term returns. The profitability progress is the general direction of Skye Bioscience,'s change in net profit over the period of time. It can combine multiple indicators of Skye Bioscience,, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Net Loss | -7.7 M | -8.1 M | |
| Income Tax Expense | 3.6 K | 2.8 K | |
| Net Interest Income | -806.3 K | -846.6 K | |
| Operating Income | -13.7 M | -14.4 M | |
| Net Loss | -37.6 M | -35.8 M | |
| Income Before Tax | -37.6 M | -35.8 M | |
| Total Other Income Expense Net | -24 M | -22.8 M | |
| Net Loss | -37.6 M | -35.8 M | |
| Interest Income | 100 K | 105 K | |
| Change To Netincome | 695.2 K | 983 K | |
| Net Loss | (5.37) | (5.64) | |
| Income Quality | 0.37 | 0.39 | |
| Net Income Per E B T | 1.00 | 0.95 |
Skye Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Skye Bioscience,. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Skye Bioscience, position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Skye Bioscience,'s important profitability drivers and their relationship over time.
Use Skye Bioscience, in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Skye Bioscience, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Skye Bioscience, will appreciate offsetting losses from the drop in the long position's value.Skye Bioscience, Pair Trading
Skye Bioscience, Common Pair Trading Analysis
The ability to find closely correlated positions to Skye Bioscience, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Skye Bioscience, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Skye Bioscience, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Skye Bioscience, Common to buy it.
The correlation of Skye Bioscience, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Skye Bioscience, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Skye Bioscience, Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Skye Bioscience, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Skye Bioscience, position
In addition to having Skye Bioscience, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run High Dividend Yield ETFs Thematic Idea Now
High Dividend Yield ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The High Dividend Yield ETFs theme has 107 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize High Dividend Yield ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
To fully project Skye Bioscience,'s future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Skye Bioscience, Common at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Skye Bioscience,'s income statement, its balance sheet, and the statement of cash flows.